Long-Term Open-Label Extension Study of Oral Levosimendan
Study sponsor: Tenax Therapeutics, Inc. · TENX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-03Estimated
Enrollment · participants800Estimated
Source updated2026-11-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.